Insulet Corporation (PODD)

Market Cap	23.40B
Revenue (ttm)	2.52B
Net Income (ttm)	246.20M
Shares Out	70.35M
EPS (ttm)	3.45
PE Ratio	96.41
Forward PE	58.61
Dividend	n/a
Ex-Dividend Date	n/a

Volume	406,582
Open	333.93
Previous Close	332.67
Day's Range	328.84 - 336.56
52-Week Range	230.05 - 353.50
Beta	1.38
Analysts	Strong Buy
Price Target	354.17 (+6.45%)
Earnings Date	Nov 6, 2025

About PODD

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is cont...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: May 15, 2007
• Employees: 3,900
• Stock Exchange: NASDAQ
• Ticker Symbol: PODD
• Website: https://www.insulet.com

Financial Performance

In 2024, Insulet's revenue was $2.07 billion, an increase of 22.07% compared to the previous year's $1.70 billion. Earnings were $418.30 million, an increase of 102.76%.

Analyst Summary

According to 18 analysts, the average rating for PODD stock is "Strong Buy." The 12-month stock price target is $354.17, which is an increase of 6.45% from the latest price.

Price Target

$354.17

(6.45% upside)

Analyst Consensus: Strong Buy